Versiti - Demin Wang, PhD | Versiti Blood Research Institute

Demin Wang, PhD

Demin  Demin  profile

Demin Wang, PhD

John B. and Judith A. Gardetto Chair for Cancer Research, Senior Investigator


Department of Microbiology & Immunology
Medical College of Wisconsin

Education and training

Doctoral Training
University of Tennessee, PhD, 1995

Postdoctoral Training
St. Jude Children’s Research Hospital, Memphis, Tennessee

Contact Information

Dr. Wang is actively engaged in investigating the differentiation process of hematopoietic stem cells (HSCs) into B lymphocytes, aiming to unveil the intricate mechanisms that govern signaling, transcriptional activities, and epigenetic regulations controling B cell biology. His research endeavors focus on the identification and functional characterization of these regulatory processes.

Recent breakthroughs in Dr. Wang's studies have brought to light a novel and pivotal signal transduction pathway crucial for the development of early B cells and the genesis of B-precursor acute lymphoblastic leukemia. These discoveries significantly contribute to advancing our comprehension of both normal B cell development and the transformative processes leading to leukemia. Importantly, these revelations open up new avenues for potential leukemia treatments.

Moreover, Dr. Wang's recent investigations have uncovered fresh insights into the mechanisms controlling the induction of tolerance in B cells. This newfound understanding serves to mitigate the risk of autoantibody production, offering potential breakthroughs in preventing autoimmune responses.

To conduct these cutting-edge investigations, Dr. Wang employs a range of state-of-the-art technologies, including CRISPR-Cas9-mediated gene editing, single-cell sequencing, ATAC-sequencing, ChIP-sequencing, CITE-sequencing, et al, and sophisticated bioinformatic analyses. The application of these advanced methodologies is poised to provide unprecedented insights into the molecular pathogenesis of human diseases, thereby paving the way for innovative strategies in the prevention and treatment of B-cell leukemia and autoimmune disorders.

  • R01 HL161127
    Wen (PI), Role: co-investigator
    02/01/22 – 01/31/26
    B-cell response and thrombotic complications in COVID-19
  • R01 HL130724
    Wang (PI)
    B cell responses in heparin-induced thrombocytopenia

Mei Yu, PhD
Research Schientist I

Yuhong Chen, PhD
Research Schientist II

Click Here for a full list of publications from Dr. Demin Wang

Selected Publications
  1. Zhang Y, Lin D, Zheng Y, Chen Y, Yu M, Cui D, Huang M, Su X, Sun Y, Chen Y, Qian Z, Carlson KS, Wen R, Wang D. MiR-9-1 controls osteoblastic regulation of lymphopoiesis.  Leukemia 2023 Nov;37(11):2261-2275. doi: 10.1038/s41375-023-02014-8. Epub 2023 Sep 5. PubMed PMID: 37670087.
  2. Flietner E, Yu M, Poudel G, Veltri AJ, Zhou Y, Rajagopalan A, Feng Y, Lasho T, Wen Z, Sun Y, Patnaik MM, Callander NS, Asimakopoulos F, Wang D, Zhang J. Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses. Oncogene. 2023 May;42(21):1751-1762. doi: 10.1038/s41388-023-02684-9. Epub 2023 Apr 8. PubMed PMID: 37031341; PubMed Central PMCID: PMC10367583.
  3. Zheng Y, Yu M, Chen Y, Xue L, Zhu W, Fu G, Morris SW, Wen R, Wang D. CARD19, a Novel Regulator of the TAK1/NF-κB Pathway in Self-Reactive B Cells. J Immunol. 2023 May 1;210(9):1222-1235. doi: 10.4049/jimmunol.2200639. PubMed PMID: 36961449; PubMed Central PMCID: PMC10156913.
  4. Zhu W, Zheng Y, Yu M, Wu Y, Wei J, Zhou L, Fu G, Schneider N, Jones C, Irani M, Padmanabhan A, Aster R, Wang D, Wen R. Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis. Blood. 2023 Mar 2;141(9):1060-1069. doi: 10.1182/blood.2022017612. PubMed PMID: 36493339; PubMed Central PMCID: PMC10023725.
  5. Wen R, Wang D. MCD-DLBCL arises from germinal center B cells. Blood. 2022 Sep 8;140(10):1058-1059. doi: 10.1182/blood.2022017534. PubMed PMID: 36074533; PubMed Central PMCID: PMC9461468.
  6. Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, Splinter NP, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan A. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood. 2022 Jul 7;140(1):73-77. doi: 10.1182/blood.2021014588. PubMed PMID: 35560046; PubMed Central PMCID: PMC9262283.
  7. Wen Z, Finn R, Gao X, Li L, Hebert A, Ranheim EA, Zhou Y, Yun G, Roose JP, Coon JJ, Shiang R, Wen R, Yu M, Wang D, Zhang J. Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in Nras(Q61R/+) mice. Leukemia. 2022 Apr;36(4):1167-1170. doi: 10.1038/s41375-022-01510-7. Epub 2022 Jan 26. PubMed PMID: 35082403; PubMed Central PMCID: PMC8983511.
  8. Bluemn T, Schmitz J, Zheng Y, Burns R, Zheng S, DeJong J, Christiansen L, Arnold O, Izaguirre-Carbonell J, Wang D, Deshpande AJ, Zhu N. Differential roles of BAF and PBAF subunits, Arid1b and Arid2, in MLL-AF9 leukemogenesis. Leukemia. 2022 Apr;36(4):946-955. doi: 10.1038/s41375-021-01505-w. Epub 2022 Jan 12. PubMed PMID: 35022500; PubMed Central PMCID: PMC10095935.
  9. Lee-Sundlov MM, Burns RT, Kim TO, Grozovsky R, Giannini S, Rivadeneyra L, Zheng Y, Glabere SH, Kahr WHA, Abdi R, Despotovic JM, Wang D, Hoffmeister KM. Immune cells surveil aberrantly sialylated O-glycans on megakaryocytes to regulate platelet count. Blood. 2021 Dec 9;138(23):2408-2424. doi: 10.1182/blood.2020008238. PubMed PMID: 34324649; PubMed Central PMCID: PMC8662070.
  10. Chen Y, Wang D. STAT5B, the dominant twin, in hematopoietic stem cells. Blood. 2021 Dec 9;138(23):2303-2305. doi: 10.1182/blood.2021013532. PubMed PMID: 34882213; PubMed Central PMCID: PMC8662072.
  11. Wen Z, Yun G, Hebert A, Kong G, Ranheim EA, Finn R, Rajagoplan A, Li S, Zhou Y, Yu M, Damnernsawad A, Roose JP, Coon JJ, Wen R, Wang D, Zhang J. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. Blood. 2021 Jun 10;137(23):3259-3271. doi: 10.1182/blood.2020009082. PubMed PMID: 33512434; PubMed Central PMCID: PMC8351901.
Join Versiti Blood Research Institute
Versiti Blood Research Institute, located in Milwaukee, Wisconsin, includes basic and clinical researchers in a variety of blood health fields.
We study the development and function of the immune system and design immunomodulating therapies for infection, autoimmune disease, and cancer.
Our Investigators
Browse our Investigators, Emeritus Investigators, and other members of the Blood Research Institute.
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.